BioNTech’s Bold Bet on Cancer: A Tumultuous Transition from Vaccine Profits
BioNTech faces a transition as COVID-19 vaccine revenue declines, focusing on mRNA-based cancer therapies. The company reports a significant financial downturn: fourth-quarter 2024 EPS fell to 1.08 euros, and full-year…